Artificial intelligence to unlock real‐world evidence in clinical oncology: A primer on recent advances

Author:

Bryant Alex K.12ORCID,Zamora‐Resendiz Rafael3,Dai Xin4,Morrow Destinee3,Lin Yuewei4,Jungles Kassidy M.5,Rae James M.56,Tate Akshay1,Pearson Ashley N.1,Jiang Ralph17,Fritsche Lars7,Lawrence Theodore S.1,Zou Weiping78910,Schipper Matthew15,Ramnath Nithya1112,Yoo Shinjae4,Crivelli Silvia3,Green Michael D.12101314ORCID

Affiliation:

1. Department of Radiation Oncology University of Michigan School of Medicine Ann Arbor Michigan USA

2. Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System Ann Arbor Michigan USA

3. Applied Mathematics and Computational Research Division, Lawrence Berkeley National Laboratory Berkeley California USA

4. Computational Science Initiative, Brookhaven National Laboratory Upton New York USA

5. Department of Pharmacology University of Michigan School of Medicine Ann Arbor Michigan USA

6. Department of Internal Medicine University of Michigan School of Medicine Ann Arbor Michigan USA

7. Department of Statistics University of Michigan Ann Arbor Michigan USA

8. Center of Excellence for Cancer Immunology and Immunotherapy University of Michigan Rogel Cancer Center Ann Arbor Michigan USA

9. Department of Pathology University of Michigan Ann Arbor Michigan USA

10. Graduate Program in Immunology University of Michigan Ann Arbor Michigan USA

11. Division of Hematology Oncology, Department of Medicine University of Michigan School of Medicine Ann Arbor Michigan USA

12. Division of Hematology Oncology, Department of Medicine Veterans Affairs Ann Arbor Healthcare System Ann Arbor Michigan USA

13. Graduate Program in Cancer Biology University of Michigan Ann Arbor Michigan USA

14. Department of Microbiology and Immunology University of Michigan School of Medicine Ann Arbor Michigan USA

Abstract

AbstractPurposeReal world evidence is crucial to understanding the diffusion of new oncologic therapies, monitoring cancer outcomes, and detecting unexpected toxicities. In practice, real world evidence is challenging to collect rapidly and comprehensively, often requiring expensive and time‐consuming manual case‐finding and annotation of clinical text. In this Review, we summarise recent developments in the use of artificial intelligence to collect and analyze real world evidence in oncology.MethodsWe performed a narrative review of the major current trends and recent literature in artificial intelligence applications in oncology.ResultsArtificial intelligence (AI) approaches are increasingly used to efficiently phenotype patients and tumors at large scale. These tools also may provide novel biological insights and improve risk prediction through multimodal integration of radiographic, pathological, and genomic datasets. Custom language processing pipelines and large language models hold great promise for clinical prediction and phenotyping.ConclusionsDespite rapid advances, continued progress in computation, generalizability, interpretability, and reliability as well as prospective validation are needed to integrate AI approaches into routine clinical care and real‐time monitoring of novel therapies.

Funder

LUNGevity Foundation

Melanoma Research Alliance

U.S. Department of Veterans Affairs

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3